Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Longer-Term DME Data Bolster Optimism Around Mechanism For Unity’s UBX1325

Executive Summary

The company announced 48-week, Phase IIa data for the drug in diabetic macular edema, an update from 24-week data the company announced in November.

You may also be interested in...



Finance Watch: Royalty Deals Pick Up As Alternative Financings Find Appeal

Public Company Edition: Seven companies revealed $2.1bn worth of royalty financings in the first quarter of 2023 and the deals keep coming in Q2, with uniQure monetizing Hemgenix royalties for up to $400m. Also, Legend grossed $350m in a follow-on offering and Athenex is liquidating via bankruptcy. 

Unity’s UBX1325 Faces Uncertain Path Forward In AMD, But DME Still Looks Promising

The company said the Phase II ENVISION study of the drug in wet age-related macular degeneration did not show non-inferiority to Eylea, leaving it with an uncertain path forward in that indication.

Unity Looks Ahead To Pivotal Study With Positive DME Data For UBX1325

The company announced 24-week results from the Phase II BEHOLD trial in diabetic macular edema patients already treated with anti-VEGF therapy, showing gains in a tough population.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel